Please assess the completion status of the following clinical trial:

Trial Title: Glaucoma Biomarkers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Either gender.~* Any self-declared ethnoracial category.~* Greater than or equal to 40 years.~* Healthy eyes with the crystalline lens, without glaucoma (cup:disc ratio \< 0.8 both eyes; asymmetry of cup:disc ratio between eyes \< 0.2).~* Open angles.~* Ability to cooperate for aqueous humor dynamic studies.~* Nonprescription and prescription topical ophthalmic products and systemic medications other than those mentioned in the exclusion criteria will be allowed during the study.~* Contact lenses removed prior to topical fluorescein instillation, and not used until the end of each fluorophotometry session.~* Able to participate on site over the multi-visit study period.~Exclusion Criteria:~* Women who are pregnant due to IOP changes.~* Any form of glaucoma, including extremely narrow angle with complete or partial closure.~* Current use of any glaucoma medication, either topically or orally.~* Chronic or recurrent inflammatory eye disease.~* Ocular trauma within the past 6 months.~* Ocular infection or ocular inflammation in the past 3 months.~* Clinically significant retinal disease.~* Any abnormality preventing reliable fluorophotometry of either eye, such as corneal scarring or severe dry eye that results in punctate fluorescein staining of the cornea.~* Intraocular surgery within 6 months.~* Serious hypersensitivity to any components of the study medications or risk from treatment with glaucoma medications, such as severe asthma or emphysema.~* Subjects must be on a stable regimen for at least 30 days prior to the Visit 1 regarding a chronic systemic medication that may affect IOP (i.e., sympathomimetic agents, beta-blockers, alpha-adrenergic agonists, alpha-adrenergic blockers, calcium channel blockers, angiotensin converting enzyme inhibitors, etc.). Any change of such medication during the study period will result in exclusion.~* Use of any glucocorticoid by any route. Subject must be washed out of the glucocorticoid for at least 2 weeks before study entry.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- timolol (Type: EXPERIMENTAL): To compare the variation in response to timolol between individuals
- latanoprost (Type: ACTIVE_COMPARATOR): To compare the variation in response to latanoprost between individuals

Based on this trial design, predict the completion outcome and termination type (if applicable).